TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Lidocaine and Esmolol to Improve the Quality of Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled to undergo abdominal surgical procedures~* Willingness and ability to sign an informed consent document~* No allergies to anesthetic or analgesic medications~* 18 - 80 years of age~* American Society of Anesthesiologists (ASA) physical status classification: Class I - III adults of either sex~* Women of childbearing potential must be currently practicing an acceptable form of birth control, and have a negative urine or blood pregnancy test~* Patients with systolic blood pressure greater than 80 and less than 150 at baseline, diastolic blood pressure less than 100 at baseline.~Exclusion Criteria:~* Inability to comprehend the pain assessment tools.~* Patients with known allergy, hypersensitivity or contraindications to anesthetic or analgesic medications~* Patients with clinically-significant medical conditions, such as brain, heart, kidney, endocrine, or liver diseases,~* Peptic ulcer disease or bleeding disorders~* Patients with history of hepatic, renal, cardiac failure, organ transplant, or diabetes~* Patients with reactive airway disease (asthma)~* Patients with seizures~* Chronic use of ß-blocker or calcium channel blocker~* Morbid obesity (body mass index \>40)~* Pregnant or lactating women~* Subjects with a history of alcohol or drug abuse within the past 3 months~* Any other conditions or use of any medication which may interfere with the conduct of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): Pre-Induction: Lidocaine Loading: 1 mg/kg Post- Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
- Esmolol (Type: ACTIVE_COMPARATOR): Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Post-Induction: Infusion dose 7.5 - 15 mcg /kg/min
- Lidocaine + Esmolol (Combo) (Type: EXPERIMENTAL): Performed with the administration of both drugs.~Pre-induction:~Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)~Post-induction:~Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Study of Early Breast Cancer Using Ultrasound

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A woman with imaging signs suggesting a diagnosis of DCIS who is scheduled for ultrasound and a biopsy is eligible for the study.~* At least 18 years of age~Exclusion Criteria:~* Pregnant or possibly pregnant or breast feeding~* Unable to provide informed consent~* Drug or multiple allergies~* Known cardiac shunts~* Known cardiac or chronic pulmonary disease~* Hypersensitivity to perflutren

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Contrast perfusion and elastography arm (Type: EXPERIMENTAL): Intravenous injection of microbubble contrast agent and elastography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phenylephrine Versus Ephedrine in Pre-eclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking~* Age ≥18 yrs~* Pre-eclampsia (mild, or severe)~* Non-laboring women~* CD under spinal anesthesia~Exclusion Criteria:~* Height \< 5'0~* Allergy to phenylephrine or ephedrine, or any other standardized medication~* Severe Cardiac disease in pregnancy with marked functional limitations (NYHA Class III and IV)~* Patients on Monoamine Oxidase Inhibitors or Tricyclic Antidepressants~* History of recent amphetamine or cocaine use.~* Subject enrollment in another study involving a study medication within 30 days of CD~* Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Phenylephrine (Type: ACTIVE_COMPARATOR): Phenylephrine for maintaining blood pressure within 10 % of baseline
- Ephedrine (Type: ACTIVE_COMPARATOR): Ephedrine for maintaining blood pressure within 10 % of baseline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Daclizumab Experience in Pediatric Heart Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Status post heart transplant~* Age 0-21 years~* Received Daclizumab as induction therapy~Exclusion Criteria:~* Those who do not meet inclusion criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Waterjet Prostate Ablation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Retention of urine refractory to medical treatment~Exclusion Criteria:~* Patients with active urinary tract infection~* Patients with bleeding disorder or on anti-coagulation~* Patients with bladder pathology including bladder stone and bladder cancer~* Patients with urethral stricture~* Patients with neurogenic bladder and/or sphincter abnormalities~* Patients with previous nonpharmacological prostate treatment,~* Prostate cancer~* Fail to give informed consent

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Aquablation (Type: EXPERIMENTAL): Surgery of benign prostatic hyperplasia by waterjet ablation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Alvimopan Use in Polytraumatized Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 to 80~* Poly-traumatized patients~* Extubated patients after abdominal exploration~* Underwent Abdominal exploration, had colon resection with primary anastomosis with closure of abdomen~Exclusion Criteria:~* Mechanically ventilated patients~* Patient not expected to survive Glasgow Coma Scale = 3~* Pregnant patients~* Apache score \> 40 (observed mortality 100%) Saas Ahmed Naved et al 2011~* Vasopressor therapy~* Septic patients~* Thoracotomy~* Bogota bag~* Intravenous Drug Abuser (IVDA) as evidenced by urine toxicology upon admission to the Trauma Unit~* Patients with prior history of gastric surgery and/or colonic surgery~* Medical History: of severe cardiovascular disease, Renal diseases, Hepatitis C or Hepatic failure, Autoimmune disease, Crohn and Ulcerative Colitis (In view of the inflammation in the intestinal mucosal which may decrease optimal absorption of the medication) and or bowel obstruction~* Prior pancreatic anastomosis or gastric anastomosis; ostomy formation~* Chronic use of nonsteroidal anti-inflammatory drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Alvimopan (Type: EXPERIMENTAL): Patients in the study group will be administered a post operative dose of Alvimopan
- Placebo (Type: PLACEBO_COMPARATOR): Patients in the Placebo group will receive a placebo pill and will be compared with the study group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Permanent residence in a selected household~* Aged 6 months- 11years for cohort study~* Informed parental consent~* For children between 8-11 years old, written assent~Exclusion criteria:~* Severely ill and unlikely to be able to complete the study~* Family does not intend to remain in the study area during the study period, or through the long rains~* Household does not accept intervention~* Not living in the study area when interventions were implemented~* enrolled in other interventional study

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- DL+LLINs (Type: EXPERIMENTAL): DL treated with abamectin and fenpyroximate
- LLINs (Type: NO_INTERVENTION): LLINs only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: French Observatory of Familial Hypercholesterolemia in Cardiology

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* coronary patients~* who agreed to participate~* high LDL-c levels: \* LDL-c\> = 1.9g / l without lipid lowering treatment according to the diagnostic score of Family Hypercholesterolemia these coronary patients with LDL\> 1.9g / l may possibly or probably be achieved Hypercholesterolemia Family.~or~\* LDL-c\> = 1.6g / l in lipid-lowering treatment, the reduction of LDL-c average expected under standard lipid-lowering therapy (statin alone) being 30-40% of these patients had therefore pretreatment levels greater than 2 g / l or greater than 2.5 g / l and may possibly or probably be achieved Family Hypercholesterolemia after the diagnostic score.~Exclusion Criteria:~* Expressed refusal to participate in the observatory~* Age ≤ 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Family Hypercholesterolemia in cardiology (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of PTSD or meets the five of the six diagnostic criteria for PTSD (event, hyperarousal, re-experiencing, duration, and distress/impaired functioning symptom criteria), but not the avoidance/numbing symptom criteria~Exclusion Criteria:~* Past or current asthma~* Diabetes or heart disease~* Currently pregnant or breastfeeding~* Concurrent use of daily benzodiazepine; daily use of antidepressant medication allowed if dose has been stable for the 3 months before study entry~* Exposure therapy or additional cognitive therapy during the course of the study (supportive psychotherapy is allowed if ongoing for at least 3 months before study entry)~* Substance abuse~* Current use of beta blockers, amiodarone, chlorpromazine, cimetidine, clonidine, or digoxin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Propranolol (Type: EXPERIMENTAL): Participants will take propranolol for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will take placebo for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Heart Failure and Risk of Re-Admissions Determined by Abnormal REVEAL Parameters

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Men and non-pregnant/non lactating women ≥ 18 years.~2. Admission to hospital or observation unit for worsening heart failure.~3. Has a Reveal XT device or has plans for a device implant for a clinical indication within 14 days of discharge.~4. Ejection fraction ≥40% by echocardiogram within 6 months of enrollment~5. Able to participate in the study for at least 6 months.~6. Not currently enrolled in another study.~7. Able to provide informed consent and complete scheduled study visits.~Exclusion Criteria:~1. Has a clinical indication for a therapeutic cardiac device (pacemaker or defibrillator)~2. History of permanent atrial fibrillation or atrial flutter.~3. History of uncontrolled hypertension (high blood pressure)~4. Has a previously implanted cardiac device (pacemaker or defibrillator) in place.~5. Stage IV or V chronic renal dysfunction (estimated GFR \<25 ml/min per 1.73 m2)~6. End-stage (Stage D) HF, including chronic ionotropic drugs infusions or left ventricular assist device~7. Waiting on the transplant list as an UNOS status 1A or 1B patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REVEAL XT device (Type: None): Subjects implanted at time of admission for HF or to be implanted within 14 days of discharge from HF hospitalization for clinical indications\>

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Chronic PLP \> 6 months~2. Short-Form McGill Pain Questionnaire Sensory Pain Rating Index raw score ≥ 16~3. Age ≥ 18 years old~4. Inpatient or Outpatient~5. Able to come to all appointments, in the opinion of the investigator~6. Able to give informed consent, in opinion of investigator~Exclusion Criteria:~1. Current Major Depressive disorder, Anxiety Disorder, or Psychotic disorder assessed by the Mini International Neuropsychiatric Interview (MINI)~2. Substance abuse or dependence within the last six months, as assessed by the MINI~3. Known Diabetes Mellitus to exclude diabetic peripheral neuropathy~4. History of coronary artery disease, hepatic disease, renal disease~5. Other pain syndromes~6. Any unstable medical conditions in the opinion of the investigator~7. Other psychotropic medications excluding hypnotics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Analgesic Techniques on Duration of Labor for Induction Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous~* American Society of Anesthesia Physical Status (ASA) 2 females~* \> 18 years old~* term (\>37 weeks gestation)~* singleton~* vertex pregnancies~* scheduled induction of labor~Exclusion Criteria:~* Non-vertex presentation~* Spontaneous labor or spontaneous rupture of membranes~* contraindication to opioid or neuraxial analgesia~* contraindication to combine spinal-epidural technique (e.g. unfavorable airway exam)~* cervical dilation \> 4.0cm~* administration of systemic hydromorphine within 4 hours of epidural request

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Group E (Type: ACTIVE_COMPARATOR): Epidural de novo technique
- Group BF (Type: ACTIVE_COMPARATOR): Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
- Group F (Type: ACTIVE_COMPARATOR): Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects from 16 to 75 years, both inclusive~* Well-characterized focal epilepsy or epileptic syndrome~* Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period~* Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED ≤ 50 % of the minimum recommended maintenance dose~Exclusion Criteria:~* Seizure type IA non-motor as only seizure type~* History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline~* Other serious uncontrolled disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Brivaracetam 50 mg (Type: EXPERIMENTAL): 50 mg/day
- Brivaracetam 100 mg (Type: EXPERIMENTAL): 100 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic heart failure of New York Heart Association Class II or III, a left ventricular ejection fraction of ≤ 40% for patients in NYHA class II or ≤ 45% for patients in NYHA class III, a hemoglobin level at the screening visit between 9.5-13.5 g/dl, and iron deficiency, which is defined as serum ferritin level \< 100µg/l or between 100 and 299 µg/l, when transferring saturation is \< 20%.~* Age ≥18 years~* Obtained informed consent~* Stable pharmacological therapy during the last 4 weeks (with the exception of diuretics)~Exclusion Criteria:~* Hemochromatosis, iron overload, defined as TSAT \> 45%~* Known hypersensitivity to Ferinject®.~* Known active infection, CRP\>20 mg/L, clinically significant bleeding, active malignancy.~* Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate transaminase (AST) above three times the upper limit of the normal range.~* Immunosuppressive therapy or renal dialysis (current or planned within the next 6 months).~* History of erythropoietin, i. v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months.~* Unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias.~* Acute myocardial infarction or acute coronary syndrome, transient ischemic attack or stroke within the last 3 months.~* Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.~* Participation in a CHF training program.~* Known HIV/AIDS.~* Inability to fully comprehend and/or perform study procedures in the investigator's opinion.~* Vitamin B12 and/or serum folate deficiency according to the laboratory (re-screening is possible after substitution therapy).~* Pregnancy or lactation.~* Participation in another clinical trial within previous 30 days and/or anticipated participation in another trial during this study.~* Anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ferric carboxymaltose (Type: ACTIVE_COMPARATOR): ferric carboxymaltose
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues